

Retinitis pigmentosa: disease mechanisms, diagnosis, and therapies

Shu, Xinhua; Pang, Ji-jing ; Zhang, Houbin ; Mansfield, David

Published in:
Journal of Ophthalmology

DOI:
[10.1155/2015/819452](https://doi.org/10.1155/2015/819452)

Publication date:
2015

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in ResearchOnline](#)

Citation for published version (Harvard):

Shu, X, Pang, J, Zhang, H & Mansfield, D 2015, 'Retinitis pigmentosa: disease mechanisms, diagnosis, and therapies', *Journal of Ophthalmology*, vol. 2015, 819452. <https://doi.org/10.1155/2015/819452>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please view our takedown policy at <https://edshare.gcu.ac.uk/id/eprint/5179> for details of how to contact us.

Editorial

Retinitis Pigmentosa: Disease Mechanisms, Diagnosis, and Therapies

Xinhua Shu,¹ Ji-jing Pang,^{2,3} Houbin Zhang,⁴ and David Mansfield⁵

¹Department of Life Sciences, Glasgow Caledonian University, Glasgow G4 0BA, UK

²School of Ophthalmology & Optometry, The Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China

³Department of Ophthalmology, College of Medicine, University of Florida, Gainesville, FL 32610, USA

⁴Sichuan Provincial Key Laboratory for Disease Gene Study, Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, China

⁵Department of Ophthalmology, Inverclyde Royal Hospital, Greenock PA16 0XN, UK

Correspondence should be addressed to Xinhua Shu; xinhua.shu@gcu.ac.uk

Received 29 April 2015; Accepted 29 April 2015

Copyright © 2015 Xinhua Shu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Retinitis pigmentosa (RP) is the most genetically and phenotypically heterogeneous disorder, characterized by the progressive death of photoreceptor cells. In recent years, huge advances have been made in understanding the disease mechanisms, identifying causal genes, and developing therapeutic strategies for this disorder. This special issue updates the knowledge of RP and presents original clinical and experimental research.

Photoreceptor cell death is known to be characterized at the early stage by caspase dependent or independent apoptosis and at late stage by necrosis, but the molecular mechanisms are not fully understood. In this special issue, S. R. Patnaik et al. review the functional role of RPGR protein complex in the pathogenesis of RP. Disease mechanisms are further elucidated in mouse (Q. Zheng et al.) and zebrafish models (Y. Liu et al. and S. Akhtar et al.). R. Migliorini et al. discuss RP associated syndromes, such as impaired ocular motility. E. Strobbe et al. report a correlation between ocular inflammation and endothelin (ET-1) plasma levels in early RP patients and suggest that anti-inflammatory therapy may slow the progression of RP.

With the development of new technologies such as next generation sequencing (NGS), more and more mutant genes that cause retinal degenerative diseases have been found. B. Gong et al. reported here a recessive RDH12 mutation identified by exome sequencing in severe early onset RP patients, which further verifies the application of NGS for molecular diagnosis of RP. Meanwhile, many naturally occurring or genetically engineered animal models have shown

gene mutations and phenotypes similar to human inherited retinal diseases, which has led to the development of a variety of therapeutic strategies for those inherited diseases regarded traditionally as incurable.

Following the success of Leber congenital amaurosis 2 (LCA2) gene therapy clinical trials, more and more vector based gene therapy clinical trials have been performed on a variety of retinal conditions including RP with MERTK mutation. AAV-mediated gene replacement therapy shows great potential to treat patients in the early stage of the disease. Gene replacement therapy combined with other approaches like treatment with histone deacetylases inhibitors (reviewed by H. Zhang et al.) or antiapoptotic/inflammatory chemicals or natural products, which can extend the therapeutic window in middle to late stages of those patients, is a potentially promising strategy for improving photoreceptor function and significantly slowing the process of retinal degeneration. Cell replacement is a promising therapeutic strategy for RP. Successful cell replacement treatments have been done in RP animal models, providing hope for RP patients and their families. Chinese medicine has a long history in the treatment of RP; combinational treatment of Chinese medicine with Western medicine may further reduce the progression of RP (reviewed by J. Xu and Q. Peng).

Xinhua Shu
Ji-jing Pang
Houbin Zhang
David Mansfield



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

